Shaun Bagai to Present at iAccess Alpha Conference
MOUNTAIN VIEW, Calif. — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a pioneering company in life sciences dedicated to developing innovative oncology therapies, has officially announced that their CEO, Shaun Bagai, will be addressing participants at the iAccess Alpha Virtual Best Ideas Fall Investment Conference. This important event will take place soon and will bring together key investors and industry experts.
Examining the Innovation and Market Demand
During his presentation on September 16, Bagai will provide insights into RenovoRx’s ongoing commercialization strategy for its pioneering drug-delivery device, RenovoCath. The goal is to address the pressing clinical needs that have emerged in the oncology market. The conversation will delve into the rising organic revenue growth due to the increasing recognition and demand for RenovoCath, not just from new clients, but also from existing ones.
Key Highlights on Clinical Trials
One of the focal points of the presentation will be the latest updates from RenovoRx’s Phase III TIGeR-PaC clinical trial. This trial is particularly vital as it assesses the product candidate involving intra-arterial delivery of gemcitabine using the RenovoCath device. This innovative approach aims to treat locally advanced pancreatic cancer (LAPC) effectively. Bagai will share the encouraging recommendation received from the Data Monitoring Committee (DMC) to continue the trial following a thorough analysis of recent interim results.
Event Details and Importance
Now, let’s talk about the key details regarding this significant investment conference:
Date: September 16-17, 2025
Presentation Time: Tuesday, September 16 at 12:30 PM ET
Webcast Link: Access the webcast for more insights.
Importance of Investor Engagement
Engagement with investors is crucial for RenovoRx as they navigate their growth trajectory in the highly competitive landscape of medical technology. Bagai will encourage investors to schedule one-on-one meetings to discuss how RenovoRx’s innovative solutions are transforming oncology treatments.
About RenovoCath and Its Applications
RenovoCath, recognized for its groundbreaking design, is intended to optimize the delivery of treatments while isolating blood flow to enhance therapeutic effects directly at tumor sites. This FDA-cleared device is not just impactful for chemotherapy delivery, but also applicable for arteriography and surgeries, showcasing its versatility in healthcare settings.
The Future of Targeted Therapies
RenovoRx is committed to addressing substantial unmet medical needs within oncology. Their technology platform, Trans-Arterial Micro-Perfusion (TAMP™), illustrates their dedication to advancing therapeutic excellence and transforming patient outcomes while minimizing side effects often associated with traditional intravenous therapies.
Continued Innovation and Commercial Success
In a significant achievement, RenovoRx has begun to commercialize RenovoCath, successfully securing its initial purchase orders. Furthermore, repeat orders from existing clients indicate a positive reception in the market, signaling strong demand for its innovative technologies. Their focus remains on expanding partnerships with medical institutions and enhancing revenue streams through strategic collaborations.
Looking Ahead
As the company moves forward, it continues to evaluate new markets and potential collaborations that can facilitate broader access to its technologies, all while focusing on the core mission of improving patient lives impacted by cancer therapies. Investors and stakeholders remain optimistic about RenovoRx’s future contributions to medical advancements.
Frequently Asked Questions
What is RenovoRx’s main product?
RenovoRx is best known for its innovative drug-delivery device, RenovoCath, designed to enhance oncology treatments.
When will Shaun Bagai present at the conference?
Shaun Bagai’s presentation is scheduled for September 16, 2025, at 12:30 PM ET.
What is the TIGeR-PaC clinical trial?
The TIGeR-PaC trial evaluates the delivery of intra-arterial gemcitabine using RenovoCath for patients with locally advanced pancreatic cancer.
How can investors learn more about RenovoRx?
Investors can access more information by attending the iAccess Alpha conference or contacting RenovoRx’s investor relations.
What regulatory approval does RenovoCath have?
RenovoCath is an FDA-cleared device intended for various therapeutic applications, including chemotherapy delivery.
